Abstract
Background
Magnetic sphincter augmentation (MSA) has emerged as an alternative surgical treatment of gastroesophageal reflux disease (GERD). The safety and efficacy of MSA has been previously demonstrated, although adequate comparison to Nissen fundoplication (NF) is lacking, and required to validate the role of MSA in GERD management.
Methods
A multi-institutional retrospective cohort study of patients with GERD undergoing either MSA or NF. Comparisons were made at 1 year for the overall group and for a propensity-matched group.
Results
A total of 415 patients (201 MSA and 214 NF) underwent surgery. The groups were similar in age, gender, and GERD-HRQL scores but significantly different in preoperative obesity (32 vs. 40 %), dysphagia (27 vs. 39 %), DeMeester scores (34 vs. 39), presence of microscopic Barrett’s (18 vs. 31 %) and hiatal hernia (55 vs. 69 %). At a minimum of 1-year follow-up, 354 patients (169 MSA and 185 NF) had significant improvement in GERD-HRQL scores (pre to post: 21–3 and 19–4). MSA patients had greater ability to belch (96 vs. 69 %) and vomit (95 vs. 43 %) with less gas bloat (47 vs. 59 %). Propensity-matched cases showed similar GERD-HRQL scores and the differences in ability to belch or vomit, and gas bloat persisted in favor of MSA. Mild dysphagia was higher for MSA (44 vs. 32 %). Resumption of daily PPIs was higher for MSA (24 vs. 12, p = 0.02) with similar patient-reported satisfaction rates.
Conclusions
MSA for uncomplicated GERD achieves similar improvements in quality of life and symptomatic relief, with fewer side effects, but lower PPI elimination rates when compared to propensity-matched NF cases. In appropriate candidates, MSA is a valid alternative surgical treatment for GERD management.
Similar content being viewed by others
References
Dent J, El-Serag HB, Wallander MA, Johansson S (2005) Epidemiology of gastroesophageal reflux disease: a systematic review. Gut 54:710–717
Toghanian S, Johnson DA, Stalhammar NO, Zerbib R (2011) Burden of gastroesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy; a post hoc analysis of the 2007 National Health and Wellness Survey. Clin Drug Investig 31:703–715
Ying C (2015) Gastroesophageal reflux disease and non-digestive tract diseases. Expert Rev Gastroenterol Hepatol 9:685–692
Lord RVN, DeMeester SR, Peters JH, Hagen JH, Elyssnia D, Sheth CT, DeMeester TR (2009) Hiatal hernia, lower esophageal sphincter incompetence and effectiveness of Nissen fundoplication in the spectrum of gastroesophageal reflux disease. J Gastrointest Surg 13:602–610
El-Serag HB (2007) Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 5:17–26
Lagergren J, Bergstrom R, Lindgren A, Nyren O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. NEJM 340:825–831
Lundell L, Miettinen P, Myrvold HE, Hatlebakk JG, Wallin L, Engstrom C, Julkunen R, Montgomery M, Malm A, Lind T, Walan A, Nordic GERD Study Group (2009) Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol 7:1292–1298
Galmiche JP, Hatlebakk J, Attwood S, Ell C, Fiocca R, Eklund S, Langstrom G, Lind T, Lundell L (2011) Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 305:1969–1977
Stein HJ, Barlow AP, DeMeester TR, Hinder RA (1992) Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux. Ann Surg 216:35–43
Finks J, Wei Y, Birkmeyer J (2006) The rise and fall of antireflux surgery in the United States. Surg Endosc 20:1698–1701
Katz PO, Zavala S (2010) Proton pump inhibitors in the management of GERD. J Gastrointest Surg 14(S1):S62–S66
Kahrilas P, Jonsson A, Denison H, Wernersson B, Hughes N, Howden C (2012) Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 10:612–619
Kahrilas PJ (2008) Gastroesophageal reflux disease. NEJM 359:1700–1707
Castell DO, Kahrilas PJ, Richer JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG (2002) Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 97:575–583
Tauseef A, David RN, William TM (2009) Long term safety concerns with proton pump inhibitors. Am J Med 122:896–903
Bonavina L, Saino GI, Bona D, Lipham J, Ganz RA, Dunn D, DeMeester T (2008) Magnetic augmentation of the lower esophageal sphincter: results of a feasibility clinical trial. J Gastrointest Surg 12:2133–2140
Wileman SM, McCann S, Grant AM, Krukowski ZH (2010) Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev 13:332–341
Varban OA, McCoy TP, Westcott C (2011) A comparison of preoperative comorbidities and post operative outcomes among patients undergoing laparoscopic nissen fundoplication at high and low volume centers. J Gastrointest Surg 15:1121–1127
Peters JH, DeMeester TR, Crookes P, Oberg S, Vos Shoop M, Hagen JA, Bremner CG (1998) The treatment of gastroesophageal reflux disease with laparoscopic Nissen fundoplication. A prospective evaluation of 100 patients with typical symptoms. Ann Surg 228(1):40–50
Dellemagne B, Weerts J, Markiewics S, Dewandre JM, Wahlen C, Monami B, Jehaes C (2006) Clinical results of laparoscopic fundoplication at ten years after surgery Surg. Endoscopy 20:159–165
Kelly J, Watson D, Chin K, Devitt P, Game P, Jamieson G (2007) Laparoscopic Nissen fundoplication: clinical outcomes at 10 years. J Am Coll Surg 205:570–575
Morgenthal C, Shane M, Steval A, Gletsu N, Milam G, Milam G, Swafford V, Hunter JG, Smith CD (2007) The durability of laparoscopic Nissen fundoplication: 11 year outcomes. J Gastrointest Surg 11:693–700
Hunter J, Smith C, Branum G, Waring J, Trus T, Cornwell M, Galloway K (1999) Laparoscopic fundoplication failures: patterns of failure and response to fundoplication. Ann Surg 230:595–606
Lipham JC, Taiganides PA, Louie BE, Ganz RA, DeMeester TR (2014) Safety analysis of first 1000 patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease. Dis Esophagus. doi:10.1111/dote.12199
Riegler M, Sebastian FS, Bonavina L, Ashton D, Horbach T, Kemen M (2014) Magnetic sphincter augmentation and fundoplication for GERD in clinical practice: one year results of a multicenter, prospective observational study. Surg Endosc 29(5):1123–1129
Catarci M, Gentileschi P, Papi C, Carrara A, Marrese R, Gaspari L, Grassi GB (2004) Evidence based appraisal of antireflux fundoplication. Ann Surg 23:325–337
Wang YR, Dempsey DT, Richter JE (2011) Trends and perioperative outcomes in inpatient antireflux surgery in the United States, 1993–2006. Dis Esophagus 24:215–223
Richter JE (2013) Gastroesophageal reflux disease treatment: side effects and complications of fundoplication. Clin Gastroeneterol Hepatol 11:465–471
Carlson MA, Frantzides CT (2001) Complications and results of primary minimally invasive antireflux procedures: a review of 10735 reported cases. J Am Coll Surg 193:428–439
Ganz RA, Gostout CJ, Grudem J, Swanson W, Berg T, DeMeester TR (2008) Use of a magnetic sphincter for the treatment of GERD: a feasibility study. Gastrointest Endosc 67(2):287–294
Ganz RA, Peters JH, Horgan S, Bermelman WA, Dunst CM, Edmondowicz SA, Lipham JC, Lukitich JD, Melvin WS, Oelschlager BK, Schlack-Haerere SC, Smith CD, Smith CC, Dunn D, Taiganides PA (2013) Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med 368:719–727
Bonavina L, Saino G, Bona D, Sironi A, Lazzari V (2013) One hundred consecutive patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease: 6 years of clinical experience from a single center. J Am Coll Surg 17:577–585
Bonavina L, DeMeester T, Fockens P, Dunn D, Saino G, Bona D, Lipham J, Bemelman W, Ganz R (2010) Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure. One and 2 year results of a feasibility trail. Ann Surg 252(5):857–862
Lipham JC, DeMeester TR, Ganz RA, Bonavina L, Saino G, Dunn DH, Fockens P, Bemelman W (2012) The LINX reflux management system: confirmed safety and efficacy now at 4 years. Surg Endosc 26:2944–2949
Louie BE, Farivar AS, Shultz D, Brennan C, Vallieres E, Aye RW (2014) Short term outcomes using magnetic sphincter augmentation versus nissen fundoplication for medically resistant gastroesophageal reflux disease. Ann Thorac Surg 98(2):498–504
Sheu EG, Nau P, Nath B, Kuo B, Rattner DW (2015) A comparative trial of laparoscopic magnetic sphincter augmentation and nissen fundoplication. Surg Endosc 29:505–509
Reynolds J, Zehetner J, Wu P, Shah S, Bildzukewicz Lipham J (2015) Laparoscopic magnetic sphincter augmentation versus laparoscopic Nissen fundoplication: a matched pair analysis of 100 patients. J Am Coll Surg 221(1):123–128
Simorov A, Ranade A, Jones R, Tadaki C, Shostrom V, Boilesen E (2014) Long term patient outcomes after laparoscopic anti reflux procedures. J Gastrointest Surg 18(1):157–162
Acknowledgments
Dr. Heather Warren’s Advanced Gastrointestinal Surgery Fellowship at Swedish Medical Center was supported in part by the Ryan Hill Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Drs. Lipham, Taiganides and Louie have received consulting fees from Torax Medical. Drs. Warren, Reynolds, Zehetner, Bildzukewicz, Aye, and Farivar, and Ms. Mickley have no conflicts of interest or financial ties to disclose.
Rights and permissions
About this article
Cite this article
Warren, H.F., Reynolds, J.L., Lipham, J.C. et al. Multi-institutional outcomes using magnetic sphincter augmentation versus Nissen fundoplication for chronic gastroesophageal reflux disease. Surg Endosc 30, 3289–3296 (2016). https://doi.org/10.1007/s00464-015-4659-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-015-4659-y